Medtronic taps top digital and healthcare technology leaders to drive company transformation

Four external appointments include new digital innovation leader, head of global strategy and two Operating Unit President roles within the Neuroscience Portfolio

Medtronic plc (NYSE:MDT) today announced four executive appointments to further its commitment to become the global leader in healthcare technology.

Mira Sahney

  • Bob Hopkins , head of global strategy, effective today.
  • Mei Jiang , new global digital innovation leader, effective today.
  • Harry "Skip" Kiil , President of the Cranial and Spinal Technologies (CST) Operating Unit, effective Jan. 4, 2022 .
  • Mira Sahney , President of the Pelvic Health Operating Unit, effective Dec. 6, 2021 .

"We're making bold moves to lead in healthcare technology and be a destination for world-class talent," said Geoff Martha , Medtronic Chairman and Chief Executive Officer. "These executive appointments bring outside-in thinking, new skills and capabilities, and diverse perspectives to our already talented leadership team – and will continue to power Medtronic's transformation."

Bob Hopkins , head of global strategy
Hopkins will join as head of global strategy. Hopkins comes from Bank of America Merrill Lynch, where he has served as Managing Director since 2008, covering the medical technology industry, including Medtronic. Hopkins has worked with the medtech industry for more than 25 years. He has been the #1 ranked analyst in the sector for the past three years in Institutional Investor's annual survey, and ranked in the top three for the past 17 years.

In his role, Hopkins will partner with Medtronic senior leadership in the areas of strategy, business development, capital deployment and investor communication. His broad, global perspective, including insights into the companies, technologies, and trends impacting healthcare and the medical technology industry will help Medtronic continue to navigate the rapidly evolving industry.

Mei Jiang , head of global digital innovation
Jiang will join Medtronic from Iron Mountain, where she served as Senior Vice President, Global Head of Innovation, Product & Solutions.

Prior to Iron Mountain, Jiang spent six years at HP, where she most recently served as Head of Digital Innovation & Business Transformation, and Cisco, where she was Founder/CEO of a management consulting startup. Since 2000, she has led three startups into accelerated growth, and has served on multiple boards for Silicon Valley startups.

Jiang is also a member of the Forbes Technology Council and founding member of "Chief"; a private network designed for women leaders — rising VP level through CEO — to strengthen their experience in the C-suite.

In her new role, Jiang will work with leaders across the organization to test, expand, and accelerate Medtronic's data, digitization, and AI strategies, globally. This work includes using data and AI to enhance internal processes, as well as establishing new business models leveraging existing capabilities and technologies. She'll transform the company's core markets and businesses using the insights of data and AI, as well as establish enterprise-wide capabilities and resources needed to support this transformation.

Harry "Skip" Kiil, President, Cranial and Spinal Technologies Operating Unit
Kiil will join Medtronic from Smith+Nephew, where he was President of the Global Orthopaedics business, responsible for the company's reconstructive arthroplasty, robotics, trauma, and extremities businesses. Kiil has extensive experience in spine and orthopaedics, deep understanding of international markets, and expertise in leveraging technology to create and deliver an integrated ecosystem at scale.

Previously, Kiil was Executive Vice President and President of Global Commercial Operations at NuVasive, Inc. He also served as Surgical Head, Europe , Middle East , Africa , and Russia , in the Alcon Eye Care Division of Novartis Corporation, where he was responsible for leading the commercial transformation of the surgical business across developed and emerging growth markets. Before joining Alcon, Kiil spent 12 years with Stryker Corporation, where he held several leadership roles, including Vice President and General Manager for Europe , and General Manager for Japan .

In his new role, Kiil will be responsible for driving innovation and delivering therapies to markets around the world more quickly and effectively and cultivating a strong culture within Cranial and Spinal Technologies.

Mira Sahney , President, Pelvic Health Operating Unit
Sahney brings more than 25 years of executive leadership experience in the development and commercialization of innovative medical technologies across gynecology, ENT, orthopaedics, and medical robotics. Sahney will leverage her deep background in mergers and acquisitions, product marketing, and commercial strategy to lead the Pelvic Health operating unit into the increasingly competitive future of the incontinence market.

Sahney joins Medtronic from Hyalex Orthopaedics — a start-up medical device company based in Lexington, Massachusetts — where she has served as Chief Executive Officer and a member of the Board of Directors since 2017. In this role, she formed its investment syndicate and built a world-class organization.

Prior to Hyalex, Sahney held a number of business leadership roles with Smith+Nephew, including Senior Vice President and General Manager of ENT and Gynecology. She also led the sale of Smith+Nephew's gynecology business to Medtronic in 2016.

Before her tenure with Smith+Nephew, Sahney was President, CEO and Co-Founder of Myomo, Inc., an award-winning medical robotics start-up that went public in 2017. Her early career included a variety of supply chain, engineering, strategy, product management, product development, research and software roles at Flow International, the BMW Group and Boeing.

In her new role, Sahney will be responsible for driving innovation and expanding access to more patients around the world, while cultivating a strong culture within Pelvic Health.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:




Erika Winkels

Ryan Weispfenning

Public Relations

Investor Relations

+1-763-526-8478

+1-763-505-4626

Harry

Bob Hopkins

Mei Jiang

(PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-taps-top-digital-and-healthcare-technology-leaders-to-drive-company-transformation-301423692.html

SOURCE Medtronic plc

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/November2021/15/c3588.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Medtronic moves for patent infringement litigation to resume

Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

2023 Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Glen Eagle Resources Inc.

(TheNewswire)

Glen Eagle Resources Inc.

Glen Eagle Resources Inc. ( TSX VENTURE: GER) ("Glen Eagle" or the "Company")  announces that the court has homologated the judgement, ordering the Company to pay Gem Yield Bahamas Limited a compensation of $1,875,895 dollars including interest and $90,000 in penalty

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, March 21, 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
CardieX Limited

Funding Commitment Agreement Update

CARDIEX Limited (ASX:CDX) (CARDIEX, the Company) provides an update on the Funding Commitment Agreement (FCA) with C2 Ventures Pty Limited (C2V, owned by Directors Niall Cairns and Craig Cooper) as announced on 8 November 2023.

Keep reading...Show less

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

  • New pharmacokinetic data demonstrate Virtue ® SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without polymer degradation or detectable remaining polymer within 90 days of balloon delivery
  • AVIM therapy presentation highlighted recent clinical results showing favorable hemodynamic effects and long-term reduction in 24-hour ambulatory systolic blood pressure, as well as the design of the BACKBEAT global pivotal study now enrolling in collaboration with Medtronic, plc (NYSE:MDT)

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced two oral presentations were given at the Cardiovascular Research Technologies ("CRT") 2024 Meeting in Washington, D.C. One presentation featured new preclinical pharmacokinetic ("PK") data on Virtue ® Sirolimus AngioInfusion Balloon ("SAB"), a novel drug-eluting balloon angioplasty system designed to deliver a proprietary, extended-release formulation of sirolimus, SirolimusEFR™ to the vessel wall during balloon angioplasty without any coating on the balloon surface. A second presentation featured recently reported clinical data on atrioventricular interval modulation ("AVIM") therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure. The AVIM presentation also outlined the design of the currently enrolling BACKBEAT global pivotal study evaluating AVIM therapy in hypertensive pacemaker patients in collaboration with Medtronic.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×